Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib for Re-differentiation in RAI-Refractory Thyroid Cancer
NCT04554680Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Countries
- 1
- Sponsor
- National University Hospital
- Modality
- Small Molecules
- Conditions
- thyroid cancer
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in thyroid cancer, sponsored by National University Hospital. Primary endpoint: Proportion of participants attaining at least one tumor lesion with lesional dosimetry of >=2000 cGy with I-131 dose of =<300 mCi at 1 month. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Proportion of participants attaining at least one tumor lesion with lesional dosimetry of >=2000 cGy with I-131 dose of =<300 mCi
Beyond the preview
Go deeper on NCT04554680.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554680.